Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens.
Identifieur interne : 001985 ( Ncbi/Checkpoint ); précédent : 001984; suivant : 001986Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens.
Auteurs : Joshua M. Dinapoli [États-Unis] ; Alexander Kotelkin ; Lijuan Yang ; Subbiah Elankumaran ; Brian R. Murphy ; Siba K. Samal ; Peter L. Collins ; Alexander BukreyevSource :
- Proceedings of the National Academy of Sciences of the United States of America [ 0027-8424 ] ; 2007.
Descripteurs français
- KwdFr :
- Administration par voie nasale, Animaux, Cytométrie en flux, Immunisation (), Maladies transmissibles émergentes (), Maladies transmissibles émergentes (immunologie), Vaccins antiviraux (administration et posologie), Vaccins antiviraux (immunologie), Vecteurs génétiques (immunologie), Virus de la maladie de Newcastle (immunologie), Virus du SRAS (immunologie).
- MESH :
- administration et posologie : Vaccins antiviraux.
- immunologie : Maladies transmissibles émergentes, Vaccins antiviraux, Vecteurs génétiques, Virus de la maladie de Newcastle, Virus du SRAS.
- Administration par voie nasale, Animaux, Cytométrie en flux, Immunisation, Maladies transmissibles émergentes.
English descriptors
- KwdEn :
- Administration, Intranasal, Animals, Chlorocebus aethiops, Communicable Diseases, Emerging (immunology), Communicable Diseases, Emerging (prevention & control), Flow Cytometry, Genetic Vectors (immunology), Immunization (methods), Newcastle disease virus (immunology), SARS Virus (immunology), Viral Vaccines (administration & dosage), Viral Vaccines (immunology).
- MESH :
- chemical , administration & dosage : Viral Vaccines.
- immunology : Communicable Diseases, Emerging, Genetic Vectors, Newcastle disease virus, SARS Virus, Viral Vaccines.
- methods : Immunization.
- prevention & control : Communicable Diseases, Emerging.
- Administration, Intranasal, Animals, Chlorocebus aethiops, Flow Cytometry.
Abstract
The international outbreak of the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) in 2002-2003 highlighted the need to develop pretested human vaccine vectors that can be used in a rapid response against newly emerging pathogens. We evaluated Newcastle disease virus (NDV), an avian paramyxovirus that is highly attenuated in primates, as a topical respiratory vaccine vector with SARS-CoV as a test pathogen. Complete recombinant NDV was engineered to express the SARS-CoV spike S glycoprotein, the viral neutralization and major protective antigen, from an added transcriptional unit. African green monkeys immunized through the respiratory tract with two doses of the vaccine developed a titer of SARS-CoV-neutralizing antibodies comparable with the robust secondary response observed in animals that have been immunized with a different experimental SARS-CoV vaccine and challenged with SARS-CoV. When animals immunized with NDV expressing S were challenged with a high dose of SARS-CoV, direct viral assay of lung tissues taken by necropsy at the peak of viral replication demonstrated a 236- or 1,102-fold (depending on the NDV vector construct) mean reduction in pulmonary SARS-CoV titer compared with control animals. NDV has the potential for further development as a pretested, highly attenuated, intranasal vector to be available for expedited vaccine development for humans, who generally lack preexisting immunity against NDV.
DOI: 10.1073/pnas.0703584104
PubMed: 17535926
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001D96
- to stream PubMed, to step Curation: 001D96
- to stream PubMed, to step Checkpoint: 001D53
- to stream Ncbi, to step Merge: 001985
- to stream Ncbi, to step Curation: 001985
Links to Exploration step
pubmed:17535926Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens.</title><author><name sortKey="Dinapoli, Joshua M" sort="Dinapoli, Joshua M" uniqKey="Dinapoli J" first="Joshua M" last="Dinapoli">Joshua M. Dinapoli</name><affiliation wicri:level="2"><nlm:affiliation>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Kotelkin, Alexander" sort="Kotelkin, Alexander" uniqKey="Kotelkin A" first="Alexander" last="Kotelkin">Alexander Kotelkin</name></author><author><name sortKey="Yang, Lijuan" sort="Yang, Lijuan" uniqKey="Yang L" first="Lijuan" last="Yang">Lijuan Yang</name></author><author><name sortKey="Elankumaran, Subbiah" sort="Elankumaran, Subbiah" uniqKey="Elankumaran S" first="Subbiah" last="Elankumaran">Subbiah Elankumaran</name></author><author><name sortKey="Murphy, Brian R" sort="Murphy, Brian R" uniqKey="Murphy B" first="Brian R" last="Murphy">Brian R. Murphy</name></author><author><name sortKey="Samal, Siba K" sort="Samal, Siba K" uniqKey="Samal S" first="Siba K" last="Samal">Siba K. Samal</name></author><author><name sortKey="Collins, Peter L" sort="Collins, Peter L" uniqKey="Collins P" first="Peter L" last="Collins">Peter L. Collins</name></author><author><name sortKey="Bukreyev, Alexander" sort="Bukreyev, Alexander" uniqKey="Bukreyev A" first="Alexander" last="Bukreyev">Alexander Bukreyev</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2007">2007</date><idno type="RBID">pubmed:17535926</idno><idno type="pmid">17535926</idno><idno type="doi">10.1073/pnas.0703584104</idno><idno type="wicri:Area/PubMed/Corpus">001D96</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001D96</idno><idno type="wicri:Area/PubMed/Curation">001D96</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001D96</idno><idno type="wicri:Area/PubMed/Checkpoint">001D53</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001D53</idno><idno type="wicri:Area/Ncbi/Merge">001985</idno><idno type="wicri:Area/Ncbi/Curation">001985</idno><idno type="wicri:Area/Ncbi/Checkpoint">001985</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens.</title><author><name sortKey="Dinapoli, Joshua M" sort="Dinapoli, Joshua M" uniqKey="Dinapoli J" first="Joshua M" last="Dinapoli">Joshua M. Dinapoli</name><affiliation wicri:level="2"><nlm:affiliation>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Kotelkin, Alexander" sort="Kotelkin, Alexander" uniqKey="Kotelkin A" first="Alexander" last="Kotelkin">Alexander Kotelkin</name></author><author><name sortKey="Yang, Lijuan" sort="Yang, Lijuan" uniqKey="Yang L" first="Lijuan" last="Yang">Lijuan Yang</name></author><author><name sortKey="Elankumaran, Subbiah" sort="Elankumaran, Subbiah" uniqKey="Elankumaran S" first="Subbiah" last="Elankumaran">Subbiah Elankumaran</name></author><author><name sortKey="Murphy, Brian R" sort="Murphy, Brian R" uniqKey="Murphy B" first="Brian R" last="Murphy">Brian R. Murphy</name></author><author><name sortKey="Samal, Siba K" sort="Samal, Siba K" uniqKey="Samal S" first="Siba K" last="Samal">Siba K. Samal</name></author><author><name sortKey="Collins, Peter L" sort="Collins, Peter L" uniqKey="Collins P" first="Peter L" last="Collins">Peter L. Collins</name></author><author><name sortKey="Bukreyev, Alexander" sort="Bukreyev, Alexander" uniqKey="Bukreyev A" first="Alexander" last="Bukreyev">Alexander Bukreyev</name></author></analytic><series><title level="j">Proceedings of the National Academy of Sciences of the United States of America</title><idno type="ISSN">0027-8424</idno><imprint><date when="2007" type="published">2007</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Intranasal</term><term>Animals</term><term>Chlorocebus aethiops</term><term>Communicable Diseases, Emerging (immunology)</term><term>Communicable Diseases, Emerging (prevention & control)</term><term>Flow Cytometry</term><term>Genetic Vectors (immunology)</term><term>Immunization (methods)</term><term>Newcastle disease virus (immunology)</term><term>SARS Virus (immunology)</term><term>Viral Vaccines (administration & dosage)</term><term>Viral Vaccines (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Administration par voie nasale</term><term>Animaux</term><term>Cytométrie en flux</term><term>Immunisation ()</term><term>Maladies transmissibles émergentes ()</term><term>Maladies transmissibles émergentes (immunologie)</term><term>Vaccins antiviraux (administration et posologie)</term><term>Vaccins antiviraux (immunologie)</term><term>Vecteurs génétiques (immunologie)</term><term>Virus de la maladie de Newcastle (immunologie)</term><term>Virus du SRAS (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Viral Vaccines</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antiviraux</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Maladies transmissibles émergentes</term><term>Vaccins antiviraux</term><term>Vecteurs génétiques</term><term>Virus de la maladie de Newcastle</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Communicable Diseases, Emerging</term><term>Genetic Vectors</term><term>Newcastle disease virus</term><term>SARS Virus</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Immunization</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Communicable Diseases, Emerging</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Intranasal</term><term>Animals</term><term>Chlorocebus aethiops</term><term>Flow Cytometry</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Administration par voie nasale</term><term>Animaux</term><term>Cytométrie en flux</term><term>Immunisation</term><term>Maladies transmissibles émergentes</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The international outbreak of the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) in 2002-2003 highlighted the need to develop pretested human vaccine vectors that can be used in a rapid response against newly emerging pathogens. We evaluated Newcastle disease virus (NDV), an avian paramyxovirus that is highly attenuated in primates, as a topical respiratory vaccine vector with SARS-CoV as a test pathogen. Complete recombinant NDV was engineered to express the SARS-CoV spike S glycoprotein, the viral neutralization and major protective antigen, from an added transcriptional unit. African green monkeys immunized through the respiratory tract with two doses of the vaccine developed a titer of SARS-CoV-neutralizing antibodies comparable with the robust secondary response observed in animals that have been immunized with a different experimental SARS-CoV vaccine and challenged with SARS-CoV. When animals immunized with NDV expressing S were challenged with a high dose of SARS-CoV, direct viral assay of lung tissues taken by necropsy at the peak of viral replication demonstrated a 236- or 1,102-fold (depending on the NDV vector construct) mean reduction in pulmonary SARS-CoV titer compared with control animals. NDV has the potential for further development as a pretested, highly attenuated, intranasal vector to be available for expedited vaccine development for humans, who generally lack preexisting immunity against NDV.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Maryland</li></region></list><tree><noCountry><name sortKey="Bukreyev, Alexander" sort="Bukreyev, Alexander" uniqKey="Bukreyev A" first="Alexander" last="Bukreyev">Alexander Bukreyev</name><name sortKey="Collins, Peter L" sort="Collins, Peter L" uniqKey="Collins P" first="Peter L" last="Collins">Peter L. Collins</name><name sortKey="Elankumaran, Subbiah" sort="Elankumaran, Subbiah" uniqKey="Elankumaran S" first="Subbiah" last="Elankumaran">Subbiah Elankumaran</name><name sortKey="Kotelkin, Alexander" sort="Kotelkin, Alexander" uniqKey="Kotelkin A" first="Alexander" last="Kotelkin">Alexander Kotelkin</name><name sortKey="Murphy, Brian R" sort="Murphy, Brian R" uniqKey="Murphy B" first="Brian R" last="Murphy">Brian R. Murphy</name><name sortKey="Samal, Siba K" sort="Samal, Siba K" uniqKey="Samal S" first="Siba K" last="Samal">Siba K. Samal</name><name sortKey="Yang, Lijuan" sort="Yang, Lijuan" uniqKey="Yang L" first="Lijuan" last="Yang">Lijuan Yang</name></noCountry><country name="États-Unis"><region name="Maryland"><name sortKey="Dinapoli, Joshua M" sort="Dinapoli, Joshua M" uniqKey="Dinapoli J" first="Joshua M" last="Dinapoli">Joshua M. Dinapoli</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Ncbi/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001985 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd -nk 001985 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Ncbi
|étape= Checkpoint
|type= RBID
|clé= pubmed:17535926
|texte= Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/RBID.i -Sk "pubmed:17535926" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |